Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial Using AZEDRA and LUTATHERA in a Dosimetrically-determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors

NCT04614766 is registered in ClinicalTrials.gov with David Bushnell as lead sponsor.

NCT NCT04614766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04614766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial Using AZEDRA and LUTATHERA in a Dosimetrically-determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors
Lead sponsor
David Bushnell
Phase
Phase 1/2
Overall status
Withdrawn
Start date
September 30, 2022
Completion date
April 23, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastro-enteropancreatic neuroendocrine tumor, neuroendocrine tumors